Eton Pharmaceuticals, Inc. is focused on commercializing and developing rare disease therapies, including Increlex, Alkindi Sprinkle, Galzin, PKU Golike, Carglumic Acid, Betaine Anhydrous, and ...

Eton reported fourth quarter 2024 net sales of $11.6 million, an increase of 59% over the prior year period, driven primarily by strong growth of ALKINDI SPRINKLE® and Carglumic Acid.

Net product sales for the third quarter of 2024 increased 40% to $9.8 million compared to $7.0 million in the prior year period, primarily driven by growth in ALKINDI SPRINKLE and Carglumic Acid.

On the metabolic side of our portfolio, Carglumic Acid continues to shine. Once again, the product is exceeding our expectations, and we are happy with the performance.

DEER PARK, Ill. - Eton Pharmaceuticals , Inc. (NASDAQ:ETON), a company specializing in rare disease treatments, has announced the acquisition of the drug Increlex from Ipsen S.A. The transaction ...

Sales of Carglumic Acid continue to exceed the Company’s expectations. The product reported strong growth in the second quarter and has already added additional patients in the third quarter of ...

Global Carglumic Acid Market Global Carglumic Acid Market Dublin, March 08, 2024 (GLOBE NEWSWIRE) -- The "Global Carglumic Acid Market by Dosage Form, by Distribution Channel, and By Region ...